Theriva Biologics Inc (TOVX) Stock Price, Quote & News

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorect...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 417 4364

Website: therivabio.com

Address:

9605 Medical Center Drive, Suite 270, Rockville, United States

Stockkkky Aug. 18 at 10:39 AM

$TOVX with volume this can run to 7$+ 🤷 volume high volume is all we need

0 · Reply

DylanGFM Aug. 18 at 12:53 AM

$TOVX might be setting up to test that 200 EMA or even better, breaking above it back to the previous highs just above $1

0 · Reply

Mtx625 Aug. 17 at 5:01 PM

$TOVX

0 · Reply

Zipcash Aug. 17 at 4:02 PM

$TOVX Merger rumors ! $5.00 bucks Monday hearing

1 · Reply

TWITLIEDETECTOR Aug. 16 at 1:02 AM

$TOVX anyone know what triggered the spike? Thanks

1 · Reply

BearRifle Aug. 15 at 10:46 PM

$TOVX anyone attending the shareholder meeting in Spain, Aug 29…? It's at Grifol's building in Barcelona Address copied from announcement: Carrer Torrent de Can Ninou, naus 5-6, 08150 - Parets del Valles (Barcelona) Spain

0 · Reply

Gutssssssssss Aug. 15 at 10:04 PM

$DHAI $ADAP $TOVX these 3 for pm

1 · Reply

Gutssssssssss Aug. 15 at 9:44 PM

$TOVX they spend 10 mil on research and have positive result treating cancer The Company expects that its cash position of $9.5 million as of early August 2025, will be able to fund its operations into the first quarter of 2026. General and administrative expenses increased to $11.2 million for the three months ended June 30, 2025, from $1.5 million for the three months ended June 30, 2024. This increase of 662% is primarily comprised of the increase in fair value of the contingent consideration adjustment of $9.2 million due to the VIRAGE Phase 2b clinical trial of VCN-01 in PDAC achieving its primary endpoint and increased

0 · Reply

exwallstcfo Aug. 15 at 9:32 PM

Action in biotechs on a Friday nite .....VERY RARE !!! $XBI above the 200 day. .... huge development The small nano caps catching a bid $ONCY $TOVX I still believe 2nd half of year ..... still very much in play !!

1 · Reply